Abstract
Novel hormonal agents (NHAs), eg, abiraterone and enzalutamide, are standard treatment (tx) for mCRPC, but many pts develop drug resistance (some due to AR mutations) and have poor prognosis. This retrospective study evaluated real-world detection rates of AR T878 and/or H875 mutations and compared outcomes in pts whose tumors harbored these mutations (AR 878/875+) and those whose did not (AR 878/875-).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
